Company Filing History:
1 out of 1,168 
1 out of 8 Years Active: 2011
Title: Nikola Marjanovic: Innovator in Macrolide Research
Introduction
Nikola Marjanovic is a prominent inventor based in Zagreb, Croatia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of macrolide compounds with anti-inflammatory properties. With a total of 2 patents, his work has the potential to impact the treatment of various inflammatory diseases.
Latest Patents
Marjanovic's latest patents include innovative formulations of macrolides. One of his notable inventions is focused on novel semi-synthetic macrolides that exhibit anti-inflammatory activity. This invention specifically addresses 14- and 15-membered macrolides substituted at the 4″ position, along with their pharmaceutically acceptable derivatives. The patent outlines processes and intermediates for their preparation, as well as their application in treating inflammatory diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2, or IL-5. Another significant patent involves macrolide compounds that contain a biotin and photo-affinity group for macrolide target identification. This invention aims to enhance the identification of macrolide targets, thereby improving the efficacy of these compounds in therapeutic applications.
Career Highlights
Throughout his career, Nikola Marjanovic has worked with notable companies in the pharmaceutical industry. He has been associated with Glaxo Group Limited and GlaxoSmithKline Istraživački Centar Zagreb d.o.o. These experiences have provided him with a solid foundation in drug development and research.
Collaborations
Marjanovic has collaborated with several professionals in his field, including Sulejman Alihodzic and Martina Bosnar. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Nikola Marjanovic is a distinguished inventor whose work in macrolide research holds promise for the treatment of inflammatory diseases. His innovative patents and collaborations reflect his commitment to advancing pharmaceutical science.